CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
Anirudh Prahallad(Novartis (Switzerland)), Saskia M. Brachmann(Novartis (Switzerland))
Cited by 27
Related Papers
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity
|Molecular Cancer Therapeutics|2008|1.1k
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
|Proceedings of the National Academy of Sciences|2009|319